Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. (NAMS) is a clinical-stage biopharmaceutical innovator advancing obicetrapib, an oral CETP inhibitor targeting cardiovascular risk through LDL-C reduction. This page provides investors and healthcare professionals with essential updates on clinical milestones, strategic partnerships, and regulatory progress.
Access timely press releases and verified news covering Phase 3 trial results (BROOKLYN, PREVAIL), European commercialization developments, and research breakthroughs in lipid management. Our curated repository ensures transparent access to material events influencing both patient care and investment considerations.
Key updates include obicetrapib's clinical efficacy data, collaboration announcements, and progress toward addressing unmet needs in dyslipidemia treatment. Bookmark this page for structured access to NAMS' latest advancements in metabolic disease innovation.
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage biopharma company developing oral, non-statin medicines for cardiovascular disease patients, announced its participation in three major investor conferences in June 2025:
1. William Blair Growth Stock Conference (Chicago) - June 3, featuring CEO Michael Davidson presenting a corporate overview at 3:20 PM CT
2. Jefferies Global Healthcare Conference (New York) - June 4, with CFO Ian Somaiya in a fireside chat at 10:30 AM ET
3. Goldman Sachs Healthcare Conference (Miami) - June 9, featuring CEO Michael Davidson and EVP Matthew Phillipe in a fireside chat at 2:40 PM ET
Live webcasts will be available through NewAmsterdam's investor relations website, with archived replays accessible afterward.
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the 2025 RBCCM Global Healthcare Conference. Ian Somaiya, the company's Chief Financial Officer, will engage in a fireside chat on Tuesday, May 20, 2025, at 10:00 a.m. ET. The presentation will be accessible via live webcast through NewAmsterdam's investor relations website, with an archived replay available afterward.
NewAmsterdam Pharma (NAMS) has granted inducement share options to eleven new non-executive employees. The grant, approved by the Company's Compensation Committee, covers 197,000 ordinary shares under the 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $20.03, matching the closing price of NAMS shares on May 1, 2025. The options will vest over a four-year period, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments, contingent on continued employment.
NewAmsterdam Pharma will present new clinical and preclinical data for its drug obicetrapib at the 93rd European Atherosclerosis Society Congress in Glasgow. The presentations include results from the BROADWAY and TANDEM Phase 3 trials, focusing on the drug's effectiveness in treating hypercholesterolemia.
Key presentations will highlight the fixed-dose combination of obicetrapib with ezetimibe for LDL-C reduction and the drug's safety profile in high cardiovascular risk patients. Additional sessions will cover obicetrapib's impact on atherosclerosis, vascular inflammation, and its effects when combined with moderate-dose statins.
The congress, scheduled for May 4-7, 2025, will feature multiple presentations across different sessions, including late-breaker oral presentations, poster networking sessions, and workshops. The research demonstrates obicetrapib's potential as a novel, oral, low-dose therapy for patients with elevated LDL-C who don't respond well to existing treatments.
NewAmsterdam Pharma (Nasdaq: NAMS) has appointed Adele Gulfo as an independent director to its Board of Directors. Gulfo brings over three decades of healthcare industry experience, notably in launching blockbuster medicines including LIPITOR® and CRESTOR®.
The appointment comes as NewAmsterdam prepares for the potential launch of obicetrapib next year. Gulfo most recently served as CEO for Sumitomo Pharma America's Biopharma Commercial Unit, overseeing commercial and development portfolios across multiple therapeutic areas. Her previous roles include executive positions at Sumitovant Biopharma, Roivant Sciences, Pfizer (where she led the $12 billion U.S. primary care business), and AstraZeneca.
NewAmsterdam is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company has recently reported positive readouts from three pivotal Phase 3 clinical trials.
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee has approved inducement share options for five non-executive new hires, covering 133,000 ordinary shares. The options were granted under the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $18.38 per share, matching the closing market price on April 1, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
FAQ
What is the current stock price of NewAmsterdam Pharma Company N.V (NAMS)?
What is the market cap of NewAmsterdam Pharma Company N.V (NAMS)?
